title: Minimal residual disease testing in hematologic malignancies and solid cancer.
abstract: Minimal residual disease (MRD) assays are of a great value to assess treatment efficacy and may provide prognostic information. This is particularly relevant in the era of targeted therapy where the introduction of MRD monitoring has fundamentally transformed the way in which cancer patients are managed. While MRD guidelines are well-established for chronic myeloid leukemia, acute promyelocytic leukemia and acute lymphoblastic leukemia, areas for continuing development are available. High level of standardization and regular external quality control rounds and recommendations for data interpretation remain essential to improve MRD monitoring. In this review, we describe the different applications of MRD assays in most frequent hematologic malignancies and solid cancer and provide an overview of the strengths and potential weaknesses of each method.
authors.affiliation: Laboratoire de Biochimie et de Biologie Moléculaire, Assistance Publique-Hôpitaux de Marseille (AP-HM), Hôpital NORD, Marseille, France.
authors.forename: Amin
authors.initials: A
authors.lastname: Ben Lassoued
authors.forename: Vanessa
authors.initials: V
authors.lastname: Nivaggioni
authors.forename: Jean
authors.initials: J
authors.lastname: Gabert
mesh_terms: D005434:Flow Cytometry; D019337:Hematologic Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D018365:Neoplasm, Residual / Q000473:pathology*; D009369:Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D016133:Polymerase Chain Reaction
keywords: CTC; RT-qPCR; acute leukemia; chronic myeloid leukemia; circulating tumor cell; minimal residual disease; multicolor flow cytometry; standardization